复方苦参注射液联合GEMOX方案治疗中晚期胰腺癌临床疗效及对肿瘤标志物指标的影响

Clinical efficacy of Compound Kushen Injection combined with GEMOX in treatment of advanced pancreatic cancer and its influence on tumor markers

目的观察复方苦参注射液联合GEMOX治疗方案治疗中晚期胰腺癌临床疗效及对肿瘤标志物指标的影响。方法将我院96例中晚期胰腺癌患者随机分为对照组与观察组各48例。对照组采用GEMOX方案治疗,观察组采用复方苦参注射液联合GEMOX方案治疗。比较两组患者临床疗效、生存质量、体质量改善程度、副反应发生情况及血清中癌胚抗原(CEA)与糖类抗原(CA19-9)的含量。结果采用CT测量瘤体的大小,得出观察组患者临床有效率高于对照组(P<0.05);观察组临床收益率高于对照组(P<0.05)。观察组患者生存质量、体质量改善率均高于于对照组(P<0.05)。观察组患者消化道反应、肝功能异常、外周神经毒性、白细胞下降、血红蛋白下降发生率均低于对照组(P<0.05)。治疗后,两组患者CA19-9、CEA均下降;观察组患者CA19-9、CEA均低于对照组(P<0.05)。结论复方苦参注射液配合GEMOX方案明显地缩小中晚期胰腺癌患者CT测量的瘤体大小;提高生存质量,改善体质量,减少副反应的发生率。

Objective To observe the clinical efficacy of Compound Kushen Injection combined with GEMOX in treatment of advanced pancreatic cancer and its influence on tumor markers. Methods 96 patients with advanced pancreatic cancer were randomly divided into control group and observation group with 48 cases each. Control group was treated with GEMOX regimen,and observation group was treated with Compound Kushen Injection on the basis of control group. The clinical efficacy,quality of life,weight improvement,side effects,and serum CEA and CA199 levels were compared between the two groups. Results The size of the tumor was measured by CT,and it was concluded that the clinical effective rate of observation group higher than that of control group(P<0.05);the clinical return rate of observation group was higher than control group(P<0.05);the rate of life and weight improvement of patients in observation group were higher than those in control group(P<0.05);the incidence of gastrointestinal reactions,abnormal liver function,peripheral neurotoxicity,white blood cell decline,and hemoglobin decline in the observation group were lower than those in control group(P<0.05);carbohydrate antigen(CA19-9)and carcino-embronic antigen(CEA)in both groups decreased;observation group were lower than control group(P<0.05). Conclusion Compound Kushen Injection combined with GEMOX regimen can significantly reduce the tumor size measured by CT in patients with advanced pancreatic cancer;improve the quality of life,improve weight,and reduce the incidence of side effects.